NZ715985A - Beta-casein a2 and reducing or preventing symptoms of lactose intolerance - Google Patents

Beta-casein a2 and reducing or preventing symptoms of lactose intolerance

Info

Publication number
NZ715985A
NZ715985A NZ715985A NZ71598514A NZ715985A NZ 715985 A NZ715985 A NZ 715985A NZ 715985 A NZ715985 A NZ 715985A NZ 71598514 A NZ71598514 A NZ 71598514A NZ 715985 A NZ715985 A NZ 715985A
Authority
NZ
New Zealand
Prior art keywords
beta
milk
casein
lactose
symptoms
Prior art date
Application number
NZ715985A
Other languages
English (en)
Inventor
Andrew John Clarke
Malav Suchin Trivedi
Original Assignee
A2 Milk Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52280344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ715985(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by A2 Milk Co Ltd filed Critical A2 Milk Co Ltd
Priority to NZ754642A priority Critical patent/NZ754642A/en
Publication of NZ715985A publication Critical patent/NZ715985A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Husbandry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Dairy Products (AREA)
  • Confectionery (AREA)
  • Peptides Or Proteins (AREA)
NZ715985A 2013-07-12 2014-07-10 Beta-casein a2 and reducing or preventing symptoms of lactose intolerance NZ715985A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ754642A NZ754642A (en) 2013-07-12 2014-07-10 Beta-casein a2 and reducing or preventing symptoms of lactose intolerance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361845480P 2013-07-12 2013-07-12
PCT/NZ2014/000141 WO2015005804A1 (en) 2013-07-12 2014-07-10 Beta-casein a2 and reducing or preventing symptoms of lactose intolerance

Publications (1)

Publication Number Publication Date
NZ715985A true NZ715985A (en) 2022-09-30

Family

ID=52280344

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ715985A NZ715985A (en) 2013-07-12 2014-07-10 Beta-casein a2 and reducing or preventing symptoms of lactose intolerance
NZ754642A NZ754642A (en) 2013-07-12 2014-07-10 Beta-casein a2 and reducing or preventing symptoms of lactose intolerance

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ754642A NZ754642A (en) 2013-07-12 2014-07-10 Beta-casein a2 and reducing or preventing symptoms of lactose intolerance

Country Status (20)

Country Link
US (3) US20160136238A1 (https=)
EP (2) EP3542805A1 (https=)
JP (2) JP6436592B2 (https=)
KR (2) KR102367941B1 (https=)
CN (3) CN114832092A (https=)
AU (2) AU2014287862B2 (https=)
BR (1) BR112016000612B8 (https=)
CA (2) CA2917492C (https=)
CL (1) CL2016000064A1 (https=)
DK (1) DK3019180T3 (https=)
ES (1) ES2743194T3 (https=)
IL (2) IL243366B (https=)
MX (2) MX394585B (https=)
MY (2) MY190309A (https=)
NZ (2) NZ715985A (https=)
PH (2) PH12016500032B1 (https=)
RU (1) RU2671562C2 (https=)
SG (2) SG11201510707YA (https=)
WO (1) WO2015005804A1 (https=)
ZA (1) ZA201600007B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2742306T3 (es) * 2013-05-31 2020-02-13 A2 Milk Co Ltd Composición que comprende beta-caseína A2 para su uso en la prevención de la inflamación del intestino
EP3297643A4 (en) * 2015-05-22 2019-02-06 The A2 Milk Company Limited BETA-CASEIN-A2 AND ANTIOXIDATIVE CAPACITY
WO2017003300A1 (en) * 2015-06-29 2017-01-05 The A2 Milk Company Limited A2 beta-casein and viscosity of milk products
JP7394527B2 (ja) * 2016-03-30 2023-12-08 ズィ・エイツー・ミルク・カンパニー・リミテッド ベータカゼイン類および認知機能
WO2018063008A1 (en) 2016-09-30 2018-04-05 The A2 Milk Company Limited Beta-caseins and gut microbiota
NL2019906B1 (en) * 2017-11-14 2019-05-20 Ausnutria Hyproca B V Composition comprising a2 b-casein and a vegetable fat mixture
CN112205476A (zh) * 2019-07-11 2021-01-12 北京三元食品股份有限公司 β-酪蛋白A2、其组合物在促进双歧杆菌属增殖中的应用
WO2021003741A1 (zh) * 2019-07-11 2021-01-14 北京三元食品股份有限公司 β-酪蛋白A2、其组合物在促进双歧杆菌属增殖中的应用
WO2023010129A2 (en) * 2021-07-30 2023-02-02 Active Genomes Expressed Diagnostics, Corp. Methods and compositions for treating liver cancer and liver disease
CN121604896A (zh) * 2023-04-25 2026-03-03 艾尔牛奶有限公司 婴儿乳配方中的β-酪蛋白和在减少婴儿反流发作中的用途
WO2024225918A1 (en) * 2023-04-25 2024-10-31 The A2 Milk Company Limited Beta-caseins in infant milk formula and use for reducing crying episodes in infants
CN117322467A (zh) * 2023-10-11 2024-01-02 东北农业大学 A2β-酪蛋白在制备功能性食品中的应用
CN117322466A (zh) * 2023-11-02 2024-01-02 光明乳业股份有限公司 一种新型婴幼儿食用的发酵乳及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2204245C (en) 1994-11-04 2008-07-22 Robert Bartlett Elliott Method of selecting non-diabetogenic milk or milk products and milk or milk products so selected
CA2217820C (en) 1995-05-16 2011-03-01 Corran Norman Stuart Mclachlan Milk and milk products for preventing or treating heart disease
US7094949B2 (en) * 1995-05-16 2006-08-22 A2 Corporation Limited Breeding and milking cows for milk free of β-casein A1
US7029702B2 (en) * 1998-07-07 2006-04-18 Ritter Natural Sciences Llc Method for increasing lactose tolerance in mammals exhibiting lactose intolerance
AU771754B2 (en) 1999-06-29 2004-04-01 New Zealand Milk Institute Limited, The Prophylactic dietary supplement based on milk
AU9037401A (en) 2000-09-08 2002-03-22 New Zealand Dairy Board Milk containing beta-casein with proline at position 67 does not aggravate neurological disorders
US20060280802A1 (en) * 2002-10-04 2006-12-14 Campbell Julie H Therapeutic uses of beta-casein a2 and dietary supplement containing beta-casein a2
HUE044812T2 (hu) * 2003-09-23 2019-11-28 Dsm Ip Assets Bv Prolinspecifikus endoproteázok alkalmazása peptidek és fehérjék hidrolízisére
US7618669B2 (en) * 2005-06-01 2009-11-17 Mead Johnson Nutrition Company Low-lactose partially hydrolyzed infant formula
CN1899054A (zh) * 2006-07-17 2007-01-24 颜贻谦 去糖牛奶的制作方法
US20120093973A1 (en) * 2009-04-03 2012-04-19 Mukund Parthasarathy Milk-like beverages
AU2010238184B2 (en) * 2009-04-15 2014-09-04 Glanbia Nutritionals (Ireland) Limited A reduced lactose milk product and a process for the preparation thereof
DE102010009582A1 (de) * 2010-02-05 2011-08-11 Vitacare GmbH & Co. KG, 60318 Mittel zur Anwendung bei Lactasemangel und Lactoseintoleranz
MX389785B (es) * 2011-07-26 2025-03-18 Nucitec Sa De Cv Composicion nutrimental para niños que presentan reflujo, colico y/o estreñimiento.
CN103315063A (zh) * 2012-03-19 2013-09-25 基斯有限公司 可预防疾病的婴儿配方奶粉
ES2742306T3 (es) * 2013-05-31 2020-02-13 A2 Milk Co Ltd Composición que comprende beta-caseína A2 para su uso en la prevención de la inflamación del intestino
US20170086481A1 (en) * 2014-06-03 2017-03-30 Abbott Laboratories Nutritional compositions comprising a lipophilic active ingredient

Also Published As

Publication number Publication date
RU2015156804A (ru) 2017-08-17
CA2917492A1 (en) 2015-01-15
WO2015005804A1 (en) 2015-01-15
SG10201710237PA (en) 2018-01-30
SG11201510707YA (en) 2016-01-28
IL261143A (en) 2018-10-31
AU2014287862A1 (en) 2016-02-11
PH12019550112A1 (en) 2020-09-14
KR20200085375A (ko) 2020-07-14
EP3019180A4 (en) 2017-03-08
KR20160030974A (ko) 2016-03-21
US20200147173A1 (en) 2020-05-14
JP6990154B2 (ja) 2022-01-12
CL2016000064A1 (es) 2016-12-16
PH12016500032A1 (en) 2016-03-28
MX2016000308A (es) 2016-11-14
CN110800803A (zh) 2020-02-18
RU2015156804A3 (https=) 2018-05-31
MX2019012446A (es) 2020-02-03
EP3019180A1 (en) 2016-05-18
DK3019180T3 (da) 2019-08-26
PH12016500032B1 (en) 2019-10-25
AU2019203684A1 (en) 2019-06-20
BR112016000612B1 (pt) 2021-11-03
RU2018131604A3 (https=) 2022-04-19
US20220175882A1 (en) 2022-06-09
HK1223846A1 (en) 2017-08-11
IL243366B (en) 2018-11-29
KR102291660B1 (ko) 2021-08-19
JP6436592B2 (ja) 2018-12-12
BR112016000612A2 (https=) 2017-07-25
NZ754642A (en) 2022-09-30
RU2018131604A (ru) 2018-11-20
IL261143B (en) 2021-02-28
BR112016000612B8 (pt) 2022-02-22
CA3214545A1 (en) 2015-01-15
MY172939A (en) 2019-12-16
JP2018203753A (ja) 2018-12-27
MX394585B (es) 2025-03-04
KR102367941B1 (ko) 2022-02-24
JP2016523958A (ja) 2016-08-12
US20160136238A1 (en) 2016-05-19
EP3542805A1 (en) 2019-09-25
MY190309A (en) 2022-04-13
MX368912B (es) 2019-10-21
CA2917492C (en) 2023-11-14
EP3019180B1 (en) 2019-05-29
RU2671562C2 (ru) 2018-11-02
AU2014287862B2 (en) 2019-07-11
AU2019203684B2 (en) 2021-08-05
ES2743194T3 (es) 2020-02-18
CN114832092A (zh) 2022-08-02
ZA201600007B (en) 2017-11-29
CN105431156A (zh) 2016-03-23

Similar Documents

Publication Publication Date Title
AU2019203684B2 (en) Beta-casein a2 and reducing or preventing symptoms of lactose intolerance
US11911439B2 (en) Beta-casein A2 and prevention of inflammation of the bowel
HK40013850A (en) Beta-casein a2 and reducing or preventing symptoms of lactose intolerance
RU2791693C2 (ru) Бета-казеин а2 и уменьшение или предотвращение симптомов непереносимости лактозы
HK1223846B (en) Beta-casein a2 and reducing or preventing symptoms of lactose intolerance
HK40013851A (en) Beta-casein a2 and prevention of inflammation of the bowel
HK1222362B (en) Composition comprising beta-casein a2 for use in the prevention of inflammation of the bowel
NZ753622B2 (en) Beta-casein a2 and prevention of inflammation of the bowel
NZ753622A (en) Beta-casein a2 and prevention of inflammation of the bowel
NZ714912B2 (en) Beta-casein a2 and prevention of inflammation of the bowel

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE INVENTOR HAS BEEN CORRECTED TO 3493336, CLARKE, ANDREW JOHN, 14 CLEVELAND ROADPARNELLAUCKLAND, 1052, NZ; 3621340, TRIVEDI, MALAV SUCHIN, 2401 MADISON STREETHOLLYWOOD, FLORIDA 33020, US

Effective date: 20200909

ERR Error or correction

Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: BETA-CASEIN A2 AND REDUCING OR PREVENTING SYMPTOMS OF LACTOSE INTOLERANCE; FILING DATE: 18 JAN 2016; STATUS: REJECTED; KIND CODE: A1 PUBLICATION DATE: 29 JAN 2016; TITLE: BETA-CASEIN A2 AND REDUCING OR PREVENTING SYMPTOMS OF LACTOSE INTOLERANCE; FILING DATE: 04 SEP 2020; STATUS: REJECTED; KIND CODE: TITLE: BETA-CASEIN A2 AND REDUCING OR PREVENTING SYMPTOMS OF LACTOSE INTOLERANCE; FILING DATE: 15 DEC 2020; STATUS: REJECTED; KIND CODE: TITLE: BETA-CASEIN A2 AND REDUCING OR PREVENTING SYMPTOMS OF LACTOSE INTOLERANCE; FILING DATE: 03 MAR 2021; STATUS: REJECTED; KIND CODE: TITLE: BETA-CASEIN A2 AND REDUCING OR PREVENTING SYMPTOMS OF LACTOSE INTOLERANCE; F

Effective date: 20220815

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JUL 2024 BY BIRGIT KNAACK

Effective date: 20230704

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JUL 2025 BY BIRGIT KNAACK

Effective date: 20240626

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JUL 2026 BY BIRGIT KNAACK

Effective date: 20250612